T he Hippocratic Oath is an oath traditionally taken by doctors swearing to practice medicine ethically. It is widely believed to have been written by Hippocrates, the father of Western medicine, or by one of his students, in Ionic Greek. The oath is considered by many a rite of passage for practitioners of medicine. One of the essential principles of the oath is to treat the patient, but first do no harm.
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In this issue of Circulation, Goto et al 1 describe the course of medically treated patients in the Acute Catherization and Urgent Intervention Triage Strategy trial, 2 a randomized study of 3 antithrombotic regimens administered to intermediate-to high-risk patients with non-ST-elevation acute coronary syndrome (NSTEACS). Among the 4491 medically treated patients after angiographic triage, the authors found that the most powerful predictors of ischemic outcomes were angiographic rather than traditional clinical parameters. In addition, treatment with the direct thrombin inhibitor bivalirudin reduced bleeding complications in comparison with heparin without any negative impact on ischemic outcomes.
This study highlights the deficiencies of available scales of risk for NSTEACS, which include the Thrombolysis in Myocardial Infarction, 3 the Global Registry of Acute Coronary Events, 4 and the Platelet Glycoprotein IIb/IIIa in Unstable Angina Receptor Suppression Using Integrilin Therapy 5 scores. All of these parameters are based on readily available demographic and clinical parameters and do not include angiographic variables. In a study of 460 consecutive NSTEACS patients that examined the accuracy of these 3 risk scores in predicting 1-year mortality or nonfatal myocardial infarction, 6 the respective c statistics for the 3 scores were 0.760, 0.884, and 0.630. In another study of 1728 NSTEACS patients, 7 the c statistics (areas under the curves) for in-hospital mortality were 0.68 (95% CI, 0.59 to 0.77), 0.81 (95% CI, 0.73 to 0.89), and 0.80 (95% CI, 0.71 to 0.88), respectively. For 1-year mortality, the c statistics were 0.69 (95% CI, 0.64 to 0.74), 0.79 (95% CI, 0.74 to 0.83), and 0.77 (95% CI, 0.72 to 0.81), respectively. In the present analysis, 1 the medically treated patients were stratified using the Thrombolysis in Myocardial Infarction score. The rates of death, myocardial infarction, or unplanned revascularization at 1 year were 4.4%, 7.7%, and 14.3% for patients at low, intermediate, and high risk, respectively. Inclusion of the number of diseased vessels enhanced the ability to predict prognosis beyond the Thrombolysis in Myocardial Infarction risk score, supporting the routine use of angiographic screening in intermediate-to high-risk NSTEACS patients. 1 Although the inclusion criteria of the Acute Catherization and Urgent Intervention Triage Strategy trial targeted intermediate-to high-risk NSTEACS patients, among the medically treated patients in the current analysis whose angiograms were reviewed by the core laboratory, 1 26.4% had no significant coronary artery disease. These patients may have been erroneously categorized as having had NSTEACS. Altogether, approximately 1 in 3 patients in the entire Acute Catherization and Urgent Intervention Triage Strategy trial cohort did not undergo any type of revascularization. Some of these patients may have had incidental coronary artery disease, not necessarily NSTEACS. Thus, the angiographic data are initially helpful in deciding whether the patient has NSTEACS, and they then aid in determining the optimal therapy and predicting outcomes. Conversely, given that only 2 in 3 intermediate-to high-risk NSTEACS patients undergo revascularization on the basis of the coronary angiography findings, it may be prudent to obtain angiographic data noninvasively, sparing patients the inherent complications of invasive procedures, and to proceed with invasive coronary angiography and revascularization only in patients with the appropriate findings. Indeed, in the present analysis of medically treated patients who underwent triage angiographically, 3% experienced major bleeding unrelated to bypass surgery, most probably at the access site. An attractive alternative to invasive coronary angiography is multidetector computed tomography of the coronary arteries, which has been shown to aid in the treatment of patients with chest pain of uncertain origin and those with non-high-risk NSTEACS. 8, 9 It is not yet recommended for patients with intermediate-to high-risk coronary artery disease, given the notion that a substantial proportion need to undergo revascularization. As mentioned above, in the present analysis, 1 in 3 of the patients who underwent triage angiographically did not The opinions expressed in this article are not necessarily those of the editors or of the American Heart Association.
From the Department of Cardiology, Rabin Medical Center, and the undergo any revascularization. 1 Large registries of patients with moderate-to high-risk NSTEACS have demonstrated that the rate in the real-world scenario approaches 1 in 2 patients. 10 Therefore, if technology advances in the future significantly limit the contrast load and radiation exposure associated with multidetector computed tomography of the coronary arteries, and the accuracy of the test improves, then it may also become the preferred initial test for the intermediate-to high-risk population to sort out the small majority of patients who need to go on to invasive coronary angiography and revascularization and to spare these procedures for the large minority of patients. The data gleaned from the noninvasive test may also shed light on possible causes of angina among patients with "angiographically nonsignificant coronary artery disease," especially if physiological assessments complement the anatomic examinations. The recent European guidelines for NSTEACS 11 highlight the double-edged nature of present-day therapies, offering estimates of the benefit versus the harm for various treatment strategies, including antithrombotic treatment. Platelet glycoprotein IIb/IIIa inhibitors have only a marginal beneficial effect in medically treated patients with NSTEACS, but they increase the risk of bleeding by more than 50%. 12 Recent studies, 13, 14 including a substudy of the Acute Catherization and Urgent Intervention Triage Strategy trial, 14 have demonstrated that instead of administering platelet glycoprotein IIb/IIIa inhibitors and an anticoagulant "upstream" to all intermediate-to high-risk NSTEACS patients, it is safe to defer the administration of platelet glycoprotein IIb/IIIa inhibitors ad hoc, just before percutaneous coronary intervention (PCI) is performed. Therefore, it is not surprising that in the present analysis of medically treated patients, the use of platelet glycoprotein IIb/IIIa inhibitors was associated with increased risk for bleeding without any clinical benefit. The authors concluded that "The current analysis demonstrates that patients with NSTE ACS who are managed medically following angiographic triage can be safely treated with bivalirudin monotherapy." This conclusion is a bit misleading. Antithrombotic treatment per protocol was initiated only a median 4.8 hours before angiography in the present cohort. The median time from admission to randomization was 7.4 hours and from randomization to initiation of antithrombotic treatment 0.6 hours. During this time, patients could receive unfractionated or low-molecular-weight heparin. The study drugs were discontinued according to study protocol at the completion of coronary angiography or PCI. When the study drugs were initially given, the attending physician did not know whether the patient would subsequently undergo revascularization, but if the patient would not undergo revascularization, then the study drug would be stopped. Therefore, the study drugs were not deliberately given to patients who received only medical treatment. On the contrary, once the patient was to receive medical therapy, the drugs were stopped. The authors offer no pathophysiological basis for a potential benefit of 4.8 hours of bivalirudin infusion versus heparin in medically treated patients before coronary angiography, especially in those with nonsignificant coronary artery disease, other than reduction in bleeding complications. These findings should therefore not be extrapolated to pa-tients initially targeted for medical treatment over many hours. There are no substantial data, including the present analysis, to support this approach.
It seems that in the treatment of NSTEACS patients, even those considered to be at intermediate to high risk, we are walking on a tightrope. Potent antithrombotic agents, even given ad hoc, are effective in patients undergoing PCI, the salutary effect balancing the potential bleeding complications. Among patients who are not undergoing PCI, of whom some may have nonsignificant coronary artery disease, the use of potent antithrombotic agents has a marginal beneficial effect; yet, the complication rate remains significant. How, therefore, should we treat intermediate-to high-risk patients with NSTEACS to abide by our oath to first do no harm?
1. Shorten the time from diagnosis to angiography. The longer we administer antithrombotic agents, the greater the complication rates. 2. Image the coronary arteries in the safest manner to separate the patients who need to undergo revascularization from the others and to spare potent, yet potentially hazardous therapies from patients who may not have NSTEACS to begin with. This may be done using the radial approach. As mentioned above, in the future it may initially be done noninvasively. 3. Consider more potent antithrombotic regimens primarily for patients undergoing PCI, preferably on an ad hoc basis in the catheterization laboratory, accounting for the patient's general risk for bleeding complications, access site issues (eg, clean versus multiple sticks, access vessel calcification and tortuosity), and lesion anatomy. Otherwise, rely on antithrombotic regimens with emphasis on the safety profile, in which case bivalirudin seems to be a solid therapeutic option.
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